LETTER
Silicone Breast Implants and Atypical Autoimmune Disease
Eugene H. Ryan and
Walter J. Moore
15 November 1993 | Volume 119 Issue 10 | Pages 1053-1054
TO THE EDITOR:
Bridges and associates [1] have provided timely documentation of clinical and immunologic features in women with rheumatologic complaints after silicone augmentation mammoplasty. Human adjuvant disease is a connective tissue disorder that sometimes meets American College of Rheumatology criteria for the diagnosis of systemic lupus erythematosus, rheumatoid arthritis, progressive systemic sclerosis, mixed connective tissue disease, or unclassified rheumatic syndromes [1-5] and occurs 6 to 15 years after implantation mammoplasty [1-5]. We describe a 39-year-old white woman who had augmentation mammoplasty in 1982 and revision of a ruptured left implant in 1989 and who developed a skin rash and eye inflammation in the fall of 1990. Her skin lesions fit the description of those reported by Bridges and colleagues as an intermediate cutaneous scleroderma. Laboratory testing was noteworthy for a positive antinuclear antibody test result (titer, 1:320) using HEp-2 cells as the tissue substrate and a negative result for dsDNA by indirect immunofluorescence using Crithidia luciliae as substrate. Skin and eye inflammation persisted for months, despite therapy with topical skin and eye steroid preparations but resolved within 10 days of removal of the intact breast implants.
The rapid improvement after intact implant removal strongly suggests an association between her scleroderma-like reaction and the silicone breast implants. The episcleritis and conjunctivitis have not been described as a manifestation of this syndrome but clearly are seen in several rheumatic diseases. We agree that atypical autoimmune illness may occur in some women after placement of silicone breast implants [1].
1. Bridges AJ, Conley C, Wang G, Burns PE, Vasey FB. A clinical and immunological evaluation of women with silicone breast implants and symptoms of rheumatic disease. Ann Intern Med. 1993; 118:929-36.
2. Spiera H. Scleroderma after silicone augmentation mammoplasty. JAMA. 1988; 260:236-8.
3. Brozena SJ, Fenske NA, Cruse CW, Espinoza CG, Vasey FB, Germain BF, et al. Human adjuvant disease following augmentation mammoplasty. Arch Dermatol. 1988; 124:1383-6.
4. Weisman MH, Vecchione TR, Albert D, Moor LT, Mueller MR. Connective tissue disease following breast augmentation: a preliminary test of the human adjuvant disease hypothesis. Plast Reconstr Surg. 1988; 82:626-30.
5. Varga J, Jimenez S. Augmentation mammoplasty and scleroderma. Arch Dermatol. 1990; 126:1220-2.
About Letters
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
Top
References
Article
